TrialBMC cancer2014

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Michael L Maitland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.